Norwegian Health Authorities Will Keep Investigating Possible Side Effects from the AstraZeneca Vaccine

Norwegian authorities have concluded that the pause in vaccinations using AstraZeneca will be kept in place.

By Eivind Nicolai Lauritsen
Global Research, March 29, 2021
sciencenorway.no 26 February 2021
Region:
Theme:

All Global Research articles can be read in 27 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

***

Norwegian health authorities still haven’t reached a conclusion on the AstraZeneca vaccine. The pause in vaccinations will be kept in place for three more weeks. A decision will be made before April 15.

“We need to know if there have been more cases of side effects in other countries, than those we already know about. We will be working very closely with other Nordic countries, especially Denmark,” said Camilla Stoltenberg, the head of the Norwegian Institute of Public Health, to NRK.

They will also investigate if there are less serious cases of side effects that have gone unreported in other countries.

Four dead in Norway

Norway halted vaccinations with the AstraZeneca vaccine on March 11, after reports of possible serious side effects surfaced in several countries.

Four people have died from a rare combination of blood clots, low platelets and bleeding in Norway after receiving the AstraZeneca-vaccine.

A group of Norwegian doctors and researchers concluded that at least two of the deaths were caused by a powerful immune response to the vaccine on March 18.

“There is nothing in the patient history of these individuals that could give such a powerful immune response. I am confident that the antibodies we have found are the cause, and I see no other explanation than that the vaccine has triggered it,” said professor and chief physician at Oslo University Hospital, Pål Andre Holme.

Norway and Denmark still haven’t concluded

Around 120.000 people have received a dose of the AstraZeneca vaccine in Norway, with the first dose being administered on February 7. So far there have been six reported cases of a rare condition of blood clots in patients who have received the vaccine. Four of them are dead.

Several other countries, like Germany, Italy, France and Spain, also paused the use of the AstraZeneca vaccine after the early reports of side effects.

After the European Medicines Agency (EMA) concluded that the vaccine is safe and effective, almost all of these countries have resumed vaccinations using AstraZeneca.

The EMA did not consider the blood clot-report from the Norwegian team of experts, as it arrived a day after the agency finished their investigations.

Currently, Norway and Denmark are the only countries that are still not putting their doses of AstraZeneca to use.

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Berit Roald / NTB

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]